Gary Phillips yesterday replaced founder Alan Robertson as CEO of Australian biotech company Pharmaxis yesterday.
Phillips, who has been the company’s COO for five years, has stepped right into the frying pan: on Monday the company is due to respond to the American Federal Drug Administration, which dealt it a huge blow last month by recommending against approving the company’s drug, Bronchitol, which treats cystic fibrosis.
Phillips holds an MBA as well as a degree in pharmacy, and was previously a CEO of Novartis. Robertson is staying on with Pharmaxis as a consultant for a year.
ABOUT THE AUTHOR
Myriam Robin is a reporter for SmartCompany and its sister site LeadingCompany. She has degrees in economics, international studies and journalism. She likes writing about businesses taking risks and doing new things.
COMMENTS
SmartCompany is committed to hosting lively discussions. Help us keep the conversation useful, interesting and welcoming. We aim to publish comments quickly in the interest of promoting robust conversation, but we’re a small team and we deploy filters to protect against legal risk. Occasionally your comment may be held up while it is being reviewed, but we’re working as fast as we can to keep the conversation rolling.
The SmartCompany comment section is members-only content. Please subscribe to leave a comment.
The SmartCompany comment section is members-only content. Please login to leave a comment.